Plexium
  • Home
  • Platform
  • Pipeline
  • Team
  • Careers
  • News
  • Contact
Select Page

Plexium Announces Appointment of Suzanne Zoumaras as Executive Vice President, Head of Human Resources

by Plexium IT Department | Sep 29, 2022 | All Posts, Press Releases

San Diego, California, September 29, 2022 – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Suzanne Zoumaras as Executive Vice President, Head of Human Resources. Ms. Zoumaras is an...

Plexium Strengthens Leadership Team With Appointment of Daniel Sipes As Senior Vice President, Head of Technology

by Amy Conrad | Aug 24, 2022 | All Posts

San Diego, California, [August 24, 2022] – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Daniel Sipes as Senior Vice President, Head of Technology. Mr. Sipes brings over two decades of...

Plexium Appoints Percival Barretto-Ko as President and Chief Executive Officer

by Plexium IT Department | Nov 4, 2021 | All Posts, Press Releases

San Diego, Calif., November 4, 2021 – Plexium Inc., (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of experienced biopharmaceutical leader Percival Barretto-Ko as President and Chief Executive Officer...

Plexium to Present at the Solebury Trout/BMO Fall Private Company Showcase 2021

by Plexium IT Department | Oct 7, 2021 | All Posts, Press Releases

SAN DIEGO, Oct. 5, 2021 – Plexium Inc., (Plexium), a biotech company focused on discovering and developing protein degrading therapeutics directed towards historically challenging drug targets, today announced that company management will present and host one-on-one...

Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders

by Plexium IT Department | Jan 21, 2021 | All Posts, Press Releases

Company also announces appointment of biotech veteran Mike Grey as Chairman of the Board SAN DIEGO, October 19, 2020 – Plexium Inc., a biotech company focused on discovering and developing protein degrading therapeutics directed towards historically challenging drug...

Plexium Launches with $28 Million in Series A Financing

by Plexium IT Department | Oct 17, 2019 | All Posts, Press Releases

Funds will help advance Plexium’s DELPhe platform to discover novel E3 ligase-modulating therapeutics to treat cancer and neurodegenerative diseases SAN DIEGO, October 17, 2019 – Plexium today announced the launch of the company with the closing of a $28 million...
« Older Entries

Categories

  • All Posts
  • Events
  • Press Releases
  • ©2022 Plexium, Inc., All rights reserved
  • Privacy Policy
  • Terms of use
  • Twitter
  • LinkedIn
  • Facebook

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. Do not sell my personal information.
Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT